Leucine supplementation modulates body composition and early weight rebound during GLP-1 receptor agonist therapy in diet-induced obese mice

Apr 19, 2026Journal of endocrinological investigation

Leucine supplements influence body fat and early weight regain during weight-loss drug treatment in obese mice

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

Semaglutide combined with leucine may induce greater fat mass loss and higher lean mass retention in obese mice.

Leucine supplementation significantly reduced weight rebound and fat rebound after semaglutide withdrawal.
Mice treated with semaglutide and leucine maintained lean mass better than those treated with semaglutide alone.
The beneficial effects of leucine were completely eliminated when the mTORC1 signaling pathway was inhibited.
These findings suggest that leucine could enhance the effectiveness of GLP-1 receptor agonists in obesity treatment.
Results are preliminary due to the short intervention duration and limited follow-up.

AI simplified

PURPOSE: GLP-1 receptor agonists (GLP-1RAs) like semaglutide are effective for obesity treatment but may cause lean mass loss and post-discontinuation weight rebound. This study aimed to explore whether leucine supplementation alone or combined with semaglutide optimizes body composition in diet-induced obese (DIO) mice.

METHODS: Male C57BL/6J mice were fed a high-fat diet for 12 weeks to induce obesity. Obese mice were then treated for 14 days with daily subcutaneous injections of semaglutide (120 µg/kg) or vehicle, along with either 1.5% leucine in drinking water or control water, and received the muscle-targeted mTORC1 inhibitor MTP-mTORC1i (1.5 mg/kg) or vehicle three times per week. Body weight, food intake, and body composition (assessed by EchoMRI) were monitored throughout this period. Following semaglutide withdrawal, leucine supplementation and MTP-mTORC1i administration were continued to evaluate their effects on weight rebound.

RESULTS: Semaglutide combined with leucine induced greater fat mass loss and higher lean mass retention compared to semaglutide alone, without further suppressing appetite. Following semaglutide discontinuation, leucine supplementation significantly attenuated weight rebound, reduced fat rebound, and preserved lean mass. These beneficial effects were completely abrogated upon mTORC1 inhibition, underscoring the critical dependence on this signaling pathway.

CONCLUSIONS: Leucine supplementation may refine GLP-1RA-induced weight loss by favoring fat reduction and preserving lean mass, and could potentially alleviate post-discontinuation weight rebound through muscle mTORC1 activation. Given the relatively short 14-day intervention and limited post-withdrawal follow-up period, these findings should be regarded as preliminary. Leucine may represent a promising adjuvant strategy to improve obesity management, pending validation in longer-term clinical investigations.

Full Text

Full text is available at the source.

View full text (PDF) ↗View full text (HTML) ↗

Leucine supplementation modulates body composition and early weight rebound during GLP-1 receptor agonist therapy in diet-induced obese mice

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief